[Editor’s note: “9 High-Risk Stocks to Buy for Massive Rewards” was previously published in November 2019. It has since been updated to include the most relevant information available.]
Slow and steady wins the race, as the old adage goes. But slow and steady can be a bit boring. Investors looking for stocks to buy, as a rule, should focus on high-quality, and preferably, lower-risk issues.
Still, there’s room in any investor’s portfolio for higher-risk, higher-reward plays — as long as those risks are understood.
In that vein, here are nine stocks to buy that offer potentially significant rewards … and almost as much risk. None of these stocks should be a core part of a portfolio, and all have the potential to blow up in your face.
But taking those risks also creates the possibility of a major reward. It’s likely at least a few of these stocks will wind up big winners going forward.
Teva Pharmaceutical (TEVA)
Teva Pharmaceutical (NYSE:TEVA) isn’t having a great time, down more than 40% over the last year.
Teva has too much debt and too little growth. Its key drug, Copaxone, which treats multiple sclerosis, is facing generic competition from Mylan (NASDAQ:MYL), among others.
Bankruptcy likely isn’t a near-term scenario but the current trajectory suggests it could occur down the line. In short, TEVA is a classic contrarian, “buy when there’s blood in the streets” type of play. And there are reasons TEVA is one of these great (if risky) stocks to buy.
While pressure has persisted on generic drugs, but it won’t last forever.
The company has sold assets to clean up its balance sheet, which has de-risked the story somewhat. In my opinion, Teva is a better version of Valeant, but with an easier path back to normalcy, even as it faces questions about price-fixing.
It’s a risky path, but if it works TEVA could gain another 20%-plus simply by reaching a higher multiple and removing bankruptcy fears.
Scientific Games Corp (SGMS)
The story already has played out somewhat at Scientific Games (NASDAQ:SGMS), which is up more than 30% from a year ago. But the growth story isn’t necessarily over.
Only a few years ago, Scientific Games was a sleepy, low-growth provider of lottery tickets and terminals. But that changed in quick succession.
SciGames acquired slot machine manufacturers WMS Industries and Bally Technologies, the latter coming only months after Bally bought equipment maker and gaming table designer Shuffle Master. Scientific Games became the dominant supplier to the casino industry worldwide: a “one-stop-shop” for casino floors.
It also became one of the most indebted companies in the U.S. markets and still is. The combination of that debt and careful cost controls at casinos, particularly in the U.S., kept SGMS stock suppressed.
But it now looks like the long-awaited “replacement cycle” of slot machines is arriving and that could be hugely beneficial for Scientific Games and its smaller, similar rival Everi Holdings Inc (NYSE:EVRI). And considering how much leverage is still on the balance sheet, there’s a case for SGMS to clear $100 — yes, $100 — if its profit growth accelerates.
That’s not a guarantee, obviously, but it’s the nature of highly indebted companies. Leverage is a weight when those companies struggle, and it’s a springboard when they grow.
Chesapeake Energy (CHK)
In the case of Chesapeake Energy Corporation (NYSE:CHK), leverage has been a weight. After optimism about stable energy prices and Chesapeake’s improved balance sheet boosted CHK stock in 2017, it was nothing but downhill in 2018.
CHK now trades down 61% since this time last year and continues pushing multi-year lows.
I think CHK is the best, if riskiest, of the stocks to buy on higher energy prices.
Chesapeake is a risky play, but the combination of debt on the balance sheet and leverage from higher energy prices mean that with a couple of changes, CHK could soar.
Splunk (NASDAQ:SPLK), on the other hand, isn’t the cheapest stock in its space or anywhere else. The high-flying “operational intelligence” software provider trades up nearly 35% year over year.
The valuation alone shows the risk in SPLK, which suffered from wild peaks and valleys last year, as investors give the company time to grow into its valuation.
Meanwhile, Splunk continues to be a likely acquisition target. Cisco (NASDAQ:CSCO) was cited as a potential buyer in September and International Business Machines (NYSE:IBM) long thought to be a logical acquirer.
Splunk is a classic growth stock in that it, too, is high-risk and high-reward. But it looks like one of the better growth stocks to buy in what might be an over-aggressive market at the moment.
Ship Finance International (SFL)
The shipping space generally has been a “Bermuda Triangle” for investor capital, but Ship Finance International (NYSE:SFL) might be the exception to the rule.
There’s likely to be some near-term volatility and Ship Finance’s dividend, which currently yields 9.62%, could be at risk, but it’s still one of those great stocks to buy if you can handle the risk.
But this also remains one of the best plays in shipping, available for a modest premium to book value and at low-teens multiple to earnings. The industry alone, and a heavily leveraged balance sheet, both show the risk.
But if Ship Finance can make it through some choppy waters over the next few months, there’s likely a nice return for shareholders on the other side.
GW Pharmaceuticals (GWPH)
There’s no sector of the market more boom-and-bust than biotech and drug development. GW Pharmaceuticals (NASDAQ:GWPH) doubles down on that volatility by developing its drugs from marijuana.
But GW Pharmaceuticals isn’t one of those fly-by-night penny stocks to buy based on legalized weed. Which is why it popped on its Q2 marijuana-based sales. It’s a $4.14 billion pharmaceutical company with a legitimate lead product candidate in Epidiolex, aimed to treat Dravet Syndrome and Lennox-Gastaut Syndrome.
Sativex, used to treat multiple sclerosis spasticity, already is on the market. And another compound has potential uses to fight epilepsy and treat autism spectrum disorders.
Like most drug development plays, GWPH is high-risk. But there’s a reason for investors to hold long-term optimism toward the company’s pipeline. Success in getting those drugs to market likely would make GWPH an acquisition target at some point suggesting a significant upside from current levels. If it happens, analysts see GWPH stock surging near 30%.
That in turn, would suggest significant upside from current levels for GWPH stock.
Canadian Solar (CSIQ)
Considering that solar power actually is gaining an increasing share of the U.S. market, in particular, it’s surprising that solar stocks including Canadian Solar (NASDAQ:CSIQ) actually haven’t done all that well.
There are risks for CSIQ, in particular: “commoditization” and price pressure could hit margins. Still, demand for CSIQ equipment is growing, and the stock isn’t terribly highly valued.
Solar stocks are likely to stay choppy for a while, but CSIQ should have some room to run if it can get through the second half of the year.
Superior Industries International (SUP)
Superior Industries International (NYSE:SUP) is on the move again. Shipments of the company’s aluminum wheels hit a record last year and it’s starting to pay off.
Auto parts stocks as a whole have had trouble, driven by “peak auto” concerns in the space. Superior itself has had a couple of missteps that impacted margins, and profits. And with SUP one of the more indebted companies in the sector, both factors have had an amplified impact on Superior’s share price.
But there’s a reason to see a reversal as well, which is what makes SUP one of the smart stocks to buy. Near-term auto sales may be coming down, particularly in the U.S.
Last year’s acquisition of European supplier UNIWHEELS improved Superior’s position overseas. And there is room to improve execution, and hopefully, margins, going forward.
SUP does have potential downside risk, particularly if global macro concerns arise, pressuring auto sales and dropping SUP earnings further. But for contrarians who think the auto parts selloff is overdone, SUP is one of the more intriguing plays.
Chegg (NYSE:CHGG) is another of the growth stocks to buy with a high valuation and a big opportunity.
The company began as an online textbook rental company. But it wound up outsourcing that business to another provider and since has focused on becoming the dominant digital platform for U.S. college students.
And Chegg is having some success. Revenues are growing and adjusted EBITDA has turned positive after years of losses. The company’s tutors and study services businesses are growing rapidly, and it’s becoming a fixture in the college landscape.
There are risks here beyond valuation. Like so many companies, Amazon is a potential competitor down the line, given its efforts to offer free Prime services to college students. But at this point, it might simply be easier for Amazon to buy Chegg, rather than expend the resources to try and fight it.
With each passing quarter, Chegg gets more and more entrenched. And that only serves to strengthen the bull case for CHGG stock.
As of this writing, Vince Martin did not hold a position in any of the aforementioned securities.